Authorized by the US FDA, it is called Wegovy (semaglutide), which is the latest generation of drugs that can promote weight loss, reduce hunger, and increase satiety.
A new obesity drug called “cutting point” by researchers has been approved by the U.S. Food and Drug Administration (FDA). This is the first time a drug has been authorized to control weight since 2014.This medicine is called Wegovy (Simeglutide) Manufactured by the Danish pharmaceutical company Novo Nordisk, it has been approved for low-calorie diets and increased physical activity for adults who are obese or overweight, have at least one weight-related disease (such as high blood pressure, type 2 diabetes, or high cholesterol) or BMI. In particular, the FDA stated in a note that the drug is used for “Chronic weight management for patients with a body mass index (BMI) of 27 kg/m2 or higher and at least one weight-related disease or patients with a BMI of 30 kg/m2 or higher“.
Approval is after the result Four 68-week clinical trialsThree are randomized, double-blind, placebo-controlled studies (including 16-week dose escalation), and one is a randomized, double-blind, placebo-controlled study in which patients receiving Wegovy continue treatment or switch to placebo.In total, more than 2,600 people with weight-related problems have received the drug treatment, and data shows that 15% weight reduction In more than half of the participants, the average variation was about 15 kg.
The drug has been used to treat type 2 diabetes, and it has also shown improvements in reducing cardiometabolic risk factors and enhancing physical function. “No other medicine can achieve this level of weight loss. It really changes the rules of the game. -Rachel Batterham, an obesity researcher at University College London, explained after the data was released -. People will be able to achieve their goals with medication for the first time Only possible through surgery“.
Wegovy-means FDA- It works by mimicking a hormone called GLP-1 (glucagon-like peptide 1), which affects the areas of the brain that regulate appetite and food intake.The dose of the drug-subcutaneously-should be gradually increased to 2.4 mg once a week within 16-20 weeks to reduce gastrointestinal side effects“.
In addition to weight loss caused by drugs, Reduce hunger and increase satietyThe treatment proved to be safe and well tolerated: the most common side effects are gastrointestinal, mild to moderate, including nausea, diarrhea, vomiting, constipation and abdominal (stomach) pain.